Table 4.

Subgroup analysis of EGFR and ALK mutant patients regarding iPFS and mOS and associated variables.

	iPFS (months)	p	mOS (months)	p
EGFR mutant patients
Number of BM
1–3	22.7 (19.2–26.2)	< 0.001	29.6 (26–33.2)	< 0.001
≥  4	9.7 (7.5–11.9)		14 (10.5–17.5)
Size of BM
< 3 cm	17.7 (12.9–22.5)	0.35	27.2 (22.8–31.5)	0.78
≥  3 cm	10.7 (4.3–17.2)		16.2 (3.7–28.7)
Presence of extracranial metastases
No	27.1 (13.2–41)	0.03	24.9 (11.1–38.7)	0.59
Yes	16.4 (12.6–20.2)		26.5 (22.9–30.1)
ALK mutant patients
Number of BM
1–3	37.2 (23.9–50.6)	0.002	61.7 (NE-NE)	0.004
≥  4	14.4 (3.9–24.9)		33.2 (21.8–44.6)
Size of BM
< 3 cm	23.4 (16.1–30.8)	0.65	44.3 (31.7–57)	0.58
≥ 3 cm	52.5 (1.8–103.3)		61.7 (0.1–140.1)
Presence of extracranial metastases
No	87.16 (NE-NE)	0.001	NE	0.008
Yes	19.15 (10.7–27.6)		NE